In this issue:
Benefit-risk profile of aripiprazole
Prevalence of MDD during peripartum period
Trends, prevalence and burden of mental disorders
Effects of semaglutide on effort-based decision-making
Examining five FDA-approved atypical antipsychotics
Incorporating ACKR1 genotype testing into current clinical pathways
Does lemborexant improve insomnia and depressive symptoms
Risk of mortality for those with anxiety or stress-related disorders
Seasonality patterns in bipolar disorder
Antidepressant use and neurodevelopmental disorders in offspring
Please login below to download this issue (PDF)